Bayer seeks EU & Japanese approvals for aflibercept for retinopathy of prematurity in premature babies

Bayer has filed applications for a new therapeutic indication for aflibercept (solution for injection) in premature babies with treatment-requiring retinopathy of prematurity (ROP) in the EU and Japan.